Vazegepant
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
3
Phase 4
0
Earliest trial started Mar 25, 2019 (NCT03872453)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Calcitonin gene-related peptide 1INHIBITOR
CALCA inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04408794 | Phase 2/Phase 3 (Phase 3) | Jun 29, 2020 | Biohaven Pharmaceuticals Inc. |
| NCT04346615 | Phase 2/Phase 3 (Phase 3) | Apr 30, 2020 | Biohaven Pharmaceuticals Inc. |
| NCT03872453 | Phase 2/Phase 3 (Phase 3) | Mar 25, 2019 | Biohaven Pharmaceuticals Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biohaven Pharmaceuticals Inc. | For profit | 3 | 3 | 1 | 2019 |
1 organizations
Page 1 / 1